investment

Precision BioSciences, Inc. (DTIL) Shareholder/Analyst Call - Slideshow

Seeking Alpha

1 min read

0 likes

⚡ Quantum Brief

Precision BioSciences reported explosive Q4 2025 financial growth, with revenue surging 5,261% year-over-year to $34.2 million, crushing estimates by $25.13 million. Earnings per share reached $1.01, exceeding projections by $1.65, marking a dramatic turnaround from prior performance. The company’s earnings call slide deck highlighted breakthroughs in its proprietary ARCUS genome-editing platform, positioning it as a leader in precision medicine. Analysts emphasized the firm’s strategic partnerships and pipeline expansion, particularly in oncology and genetic therapies, as key revenue drivers. The March 2026 call underscored investor confidence, with leadership outlining accelerated commercialization timelines for its gene-editing technologies.

AI Audio Summary

0:00 / 0:00

Click to play

Quantum News · Media Library

Understand this faster with AI

Ask ChatGPT

Research with Perplexity

Explain with Claude

Discuss on Grok

SA Transcripts159.03K FollowersFollow5ShareSaveCommentsQ4: 2026-03-12 Earnings SummaryPR10-KEPS of $1.01 beats by $1.65 | Revenue of $34.20M (5,261.13% Y/Y) beats by $25.13MThe following slide deck was published by Precision BioSciences, Inc. in conjunction with this event. This article was written bySA Transcripts159.03K FollowersFollowSeeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team

Read Original

Source Information

Source: Seeking Alpha

Website: https://seekingalpha.com/feed.xml

Discussion

0 professional contributions

Be the first to add a constructive contribution.